

6/10/41
Dkt. 64080-JPW/ALB

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : David Stern et al.,
U.S. Serial No : 09/872,185 Group Art Unit: 1641
Filed : June 1, 2001
For : METHODS FOR TREATING INFLAMMATION

RECEIVED
APR 05 2002
TECH CENTER 1600/2900

1185 Avenue of the Americas
New York, New York 10036
March 29, 2002

U.S. Patent and Trademark Office
P.O. Box 2327
Arlington, VA 22202

Sir:

INFORMATION DISCLOSURE STATEMENT

In accordance with their duty of disclosure under 37 C.F.R. §1.56, applicants direct the Examiner's attention to the following references which are listed on the PTO-1449 form attached hereto as **Exhibit A**. Copies of these references are attached hereto as **Exhibit 1-15**

1. Baynes, J. (1991). Role of oxidative stress in development of complications in diabetes. Diabetes 40:405-412.
2. Behl, C., et al. (1994). Hydrogen peroxide mediates amyloid β protein toxicity. Cell 77, 817-827;

Applicants : David M. Stern, et al.
Serial No. : 09/872,185
Filed : June 1, 2001
Page 2

3. Vlassara, H., et al. (1994). Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging. *Lab. Invest.* 70: 138-151.
4. Schmidt, A.M., SD Yan, and D. Stern. (1995). The dark side of glucose (News and Views). *Nature Medicine* 1:1002-1004.
5. Schmidt, A.M., Vianna, M., Gerlach, M., Brett, J., Ryan, J., Kao, J., Esposito, C., Hegarty, H., Hurley, W., Clauss, M., Wang, F., Pan, Y.C., Tsang, T.C., and Stern, D. (1992). Isolation and characterization of binding proteins for Advanced Glycosylation Endproducts from lung tissue which are present on the endothelial cell surface. *J. Biol. Chem.* 267:14987-14997.
6. Brett, J, et al., (1993). Survey of the distribution of a newly-characterized receptor for AGEs in tissues. *Am. J. Pathol*, 143:1699-1712.
7. Hori, O., J. Brett, T. Slattey, R. Cao, J. Zhang, J. Chen, M. Nagashima, D. Nitecki, J. Morser, D. Stern, A.M. Schmidt. (1995). The Receptor for Advanced Glycation Endproducts (RAGE) is a cellular binding site for amphotericin: Mediation of neurite outgrowth and co-expression of RAGE and amphotericin in the developing nervous system. *J. Biol. Chem.* 270:25752-25761.

Applicants : David M. Stern, et al.
Serial No. : 09/872,185
Filed : June 1, 2001
Page 3

8. Schmidt, A-M, et al. (1994). Cellular Receptors for Advanced Glycation Endproducts. *Arterioscler. Thromb.*, 14:1521-1528.
9. Schmidt, A-M, et al. (1994). Receptor for Advanced Glycation Endproducts (AGEs) has a central role in vessel wall interactions and gene activation in response to circulating AGE proteins. *Proc. Natl. Acad. Sci. (USA)*, 91:8807-8811.
10. Sell, L., and Monnier, V. (1989). Structure elucidation of a senescence cross-link from human extracellular matrix; implication of pentoses in the aging process. *J. Biol. Chem.* 264, 21597-21602.
11. Giardino, I. et al. (1994) Nonenzymatic glycosylation in Vitro and in bovine endothelial cells after basic fibroblast growth factor activity. *J. Clin. Invest.* 94:110-117.
12. Park, L., et al. (1997). A murine model of accelerated diabetic atherosclerosis: suppression by soluble Receptor for Advanced Glycation Endproducts. *Circulation Supplement*. Abstract 3079.
13. Wautier, J.-L., et al. (1996). Interaction of diabetic erythrocytes bearing Advanced Glycation Endproducts with the endothelial receptor AGE induces generation of reactive oxygen intermediates and cellular dysfunction. *Circulation Supplement*

Applicants . David M Stern, et al.
Serial No. : 09/872,185
Filed : June 1, 2001
Page 4

94(8):4139.

14. Wu J, Rogers L, Stern D, Schmidt AM and Chiu DTW. (1997). The soluble receptor for Advanced Glycation Endproducts (sRAGE) ameliorates impaired wound healing in diabetic mice. Plastic Surgery Research Council, Abstract #77, p. 43.
15. Schmidt, A-M, et al. (1994). Cellular receptors for advanced glycation end products. *Arterioscler. Thromb.*, 14:1521-1528.


Summary

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorney invites the Examiner to telephone at the number provided below.


Applicants : David Stern, et al.
Serial No. : 09/872,185
Filed : June 1, 2001
Page 5

Pursuant to 37 C.F.R. §1.97(b)(3) no fee is deemed necessary in connection with the filing of the Information Disclosure Statement. However, if any fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 03-3125.

Respectfully submitted,



John P. White
Registration No. 28,678
Attorney for Applicant(s)
Cooper & Dunham, LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231.	
	3/29/02
John P. White Reg. No. 28,678	Date